Micoy Therapeutics is a Jersey City, New Jersey-based biotechnology company pioneering therapies to block harmful autoantibodies and strengthen immune defenses.

We are dedicated to revolutionizing the treatment of life-threatening viral infections and cancer by addressing a previously overlooked vulnerability: the presence of harmful autoantibodies that impair the immune system’s ability to combat viruses or respond effectively to anticancer therapy.

Micoy Therapeutics develops targeted therapies and companion diagnostics, including the NeuroLume™ rapid test for Folate Receptor Autoantibodies (FRAAs) and decoy biologics to neutralize Type I Interferon Autoantibodies. Our innovative approach combines immunology, protein engineering, and diagnostic innovation to detect and neutralize these autoantibodies early, restoring immune balance and protecting individuals from a wide range of viral threats.

Led by a team of experts in drug discovery, immunology, and translational medicine, Micoy Therapeutics is building a platform for immune health across the lifespan, revealing how autoantibodies shape human health and creating practical solutions to restore balance and resilience.

Decoy Biologics | Micoy Therapeutics

Product description

Micoy Therapeutics Jersey City, United States (US)

Price: N/A

Micoy Therapeutics
Jersey City, United States (US)